Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00418795
Other study ID # rhPBGD-02
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received January 4, 2007
Last updated March 7, 2018
Start date June 11, 2003
Est. completion date June 20, 2006

Study information

Verified date March 2018
Source Chiesi Farmaceutici S.p.A.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A multi-centre, double-blind, randomized, placebo controlled, parallel group trial, investigating the efficacy and safety of Porphozym (recombinant human porphobilinogen deaminase)in the treatment of acute attacks in AIP.


Description:

The primary objective is: To investigate the biochemical efficacy on plasma porphobilinogen (PBG) of Porphozy(recombinant human porphobilinogen deaminase) in subjects with Acute Intermittent Porphyria (AIP) during an attack and the clinical efficacy clinical efficacy of Porphozymâ„¢, being the change in pain from baseline to 24 hours after start of treatment. The correlation between the biochemical and clinical efficacy is investigated as well. Further the safety of Porphozymâ„¢ is evaluated.

After a screening period lasting as short as possible subjects enrolled in the trial will be randomized to treatment with either Porphozymâ„¢ or placebo. Treatment is given over 48 hours. After end of treatment, the subject enters the observation period, which lasts until the discharge from the hospital. Subjects are followed up with visits 14 and 28 days after end of treatment. Additional safety follow-up will be performed 2, 4 and 6 months after end of treatment. At least 36 Subjects will be enrolled in the trial.

The trial drug,is supplied by Zymenex A/S, Denmark in vials for reconstitution in water for injections (WFI).

At start of treatment a bolus injection iv is given to decrease PBG levels ot zero. This is followed by continuous iv infusion of the enzyme over the following 48 hours.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date June 20, 2006
Est. primary completion date June 20, 2006
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Informed consent

- Confirmed diagnosis of AIP

- Previous attacks with PBG above the reference level of the laboratory AND exclusion of variegate porphyria (florescence emission of plasma samples is maximal at 626 nm in VP) AND exclusion of hereditary coproporphyria (HCP) (increased ratio of fecal coproporphyrin III to coproporphyrin I found in HCP)

- Acute attack of AIP verified by presence of abdominal and/or back and/or limb pain, diagnosed by the investigator as being caused by AIP

- Urine PBG above 6 mmol/mol creatinine (5 times upper reference level of the central laboratory)

- Male or female aged above 18 year

Exclusion criteria are:

- First acute attack in AIP

- Other reasons for abdominal and/or back and/or limb pain as judged by the investigator

- Therapy with human hemin within 7 days prior to administration of trial drug

- Treatment with any investigational drug within 4 weeks prior to this trial

- Known or suspected allergy to the trial product or related products

- Pregnant or breast-feeding women and women who intend to become pregnant prior to or during the trial

- Women of child-bearing potential who are not using acceptable methods of contraception (systemic contraception, IUD, barrier method or GnRH analogues)

- Previous documented renal impairment defined as above 150 mmol/L or 1.7 mg/dL serum creatinine, indicating a reduction in kidney function of 50% or more

- Any disease or condition that the investigator judges would interfere with the trial

- Previous randomization in this trial

Study Design


Intervention

Drug:
recombinant human porphobilinogen deaminase (Porphozym)


Locations

Country Name City State
United States Univercity Texas Medical Branch Galveston Texas

Sponsors (1)

Lead Sponsor Collaborator
Zymenex A/S

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Plasma PBG
See also
  Status Clinical Trial Phase
Terminated NCT02922413 - Panhematin for Prevention of Acute Attacks of Porphyria Phase 2
Completed NCT02949830 - A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP) Phase 1/Phase 2
Completed NCT02943213 - Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride Phase 1
Completed NCT02082860 - Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria Phase 1
Completed NCT03338816 - ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP) Phase 3
Completed NCT02452372 - A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP) Phase 1
Active, not recruiting NCT01617642 - Dental Health, Diet, Inflammation and Biomarkers in Patients With Acute Intermittent Porphyria(AIP)
Completed NCT02076763 - Observational Study of Acute Intermittent Porphyria Patients N/A
Active, not recruiting NCT02935400 - Acute Porphyria Biomarkers for Disease Activity